Clinical Trials Logo

Drug-Induced Liver Injury clinical trials

View clinical trials related to Drug-Induced Liver Injury.

Filter by:

NCT ID: NCT02734966 Completed - Clinical trials for Drug-Induced Liver Injury

Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection in Subjects With Acute Drug-induced Liver Injury

Start date: December 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the safety, effective dosage and treatment of Magnesium Isolycyrrhizinate Injection to cure the acute drug-induced liver injury compared with the Tiopronin Injection.

NCT ID: NCT02686385 Terminated - Clinical trials for Drug Induced Liver Injury

Efficacy of N-acetylcysteine With or Without Steroids in Drug Induced Liver Injury

Start date: March 1, 2016
Phase: N/A
Study type: Interventional

Intervention - Subjects will be randomized to 2 groups Group A - subjects will receive Prednisolone for 20 days with NAC (N-Acetylcysteine) Group B - will receive NAC (N-Acetylcysteine) only NAC (N-acetylcysteine) dosing Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 hour Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h - Monitoring and assessment-Liver Biopsy at baseline and at 3 months, Liver Function Test at regular intervals. - Stopping rule-Development of sepsis, worsening of Liver functions.

NCT ID: NCT02431832 Completed - Healthy Clinical Trials

Exploration of microRNA and Metabolomics Biomarkers Predicting Drug Induced Liver Injury in Elderly People

Start date: February 2015
Phase: Phase 1
Study type: Interventional

An open-label, one-sequence, multiple administration study for exploration of microRNA and metabolomics biomarkers to predict drug induced liver injury in healthy elderly Korean people.

NCT ID: NCT02407964 Completed - Clinical trials for Drug-Induced Liver Injury

A Retrospective Study on Drug Induced Liver Injury in China

DILI-R
Start date: March 2015
Phase: N/A
Study type: Observational

This is a multi-center, open-enrollment, retrospective, non-interventional epidemiologic study without any clinical treatment. Its primary objective is to understand 1) incidence of drug-induced liver injury, including incidences among all the hospitalized patient, among patients in department of hepatic diseases, digestive diseases, oncology, hematology etc., individually; 2) epidemiologic characteristics of drug-induced liver injury, including suspected medications, clinical types, histological characteristics, severity and outcomes.

NCT ID: NCT02299739 Completed - Clinical trials for Musculoskeletal Diseases

Liver Enzyme Abnormalities and Risk Factors in Taking Herbal Medicine

Start date: December 2005
Phase:
Study type: Observational

Herb-induced liver injury is an important issue in musculoskeletal diseases where herbal medicine is most frequently used. The low prevalence of drug-induced liver injury (DILI) gives rise to the need for large-scale patient studies. We assessed the prevalence of liver injury of 6,894 musculoskeletal disease inpatients taking herbal medicine.

NCT ID: NCT02182167 Completed - Clinical trials for Drug-Induced Liver Injury

A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis

NAC in TB DIH
Start date: May 2014
Phase: Phase 2/Phase 3
Study type: Interventional

We will conduct a randomized placebo controlled trial to determine whether administration of intravenous (IV) NAC to participants with TB DIH, in dosages similar to that used in paracetamol poisoning, can improve recovery from hepatotoxicity.

NCT ID: NCT02143323 Completed - Healthy Clinical Trials

A Clinical Study to Explore Biomarkers for Drug-induced Liver Injury (DILI)

Start date: December 2013
Phase: Phase 1
Study type: Interventional

This study has an open-label, one-sequence, multiple drug administration design. The purpose of this study is as follows; - To evaluate the change of liver function according to glutathione s-transferase (GST) genotype after the multiple administration of amoxicillin/clavulanate. - To evaluate the intrinsic metabolite, human leukocyte antigen (HLA) genotype, and microRNA (miRNA) based on liver function change as the candidate biomarker for DILI.

NCT ID: NCT02086708 Recruiting - Clinical trials for Non-Alcoholic Fatty Liver Disease

Ultrasound Method to Measure Fibrosis of the Liver in Children

Start date: June 2010
Phase: N/A
Study type: Interventional

HYPOTHESIS: The investigators hypothesize that sonoelastography (SE) provide accurate quantitative measurements that can be used to stage liver fibrosis in pediatric patients with chronic liver disease. Specific Aims: 1. To measure liver stiffness with sonoelastography in adults with suspect diffuse liver disease who will undergo nonfocal liver biopsy as part of their routine clinical care. 2. To assess the sensitivity and specificity of sonoelastography for the detection and staging of liver fibrosis. 3. To obtain sonoelastography values of the liver in healthy children (control subjects).

NCT ID: NCT02061826 Not yet recruiting - Clinical trials for Drug-induced Liver Injury

Establishment of Drug-induced Liver Injury Databases and Application of Circulating microRNA(miRNA)

Start date: May 2014
Phase: N/A
Study type: Observational [Patient Registry]

The purpose of the study is to establish drug-induced liver injury databases in China, make criteria for Chinese drug-induced liver injury patients and evaluate the application of certain circulating miRNA in diagnosis or treatment of drug-induced liver injury.

NCT ID: NCT01747772 Recruiting - Clinical trials for Non-Alcoholic Fatty Liver Disease

Sonoelastography: Ultrasound Method to Measure Liver Fibrosis

Start date: February 2010
Phase: N/A
Study type: Interventional

HYPOTHESIS: The investigators hypothesize that sonoelastography (SE) provide accurate quantitative measurements that can be used to stage liver fibrosis in patients with chronic liver disease. 1. To measure liver stiffness with sonoelastography in adults with suspect diffuse liver disease who will undergo nonfocal liver biopsy as part of their routine clinical care. 2. To assess the sensitivity and specificity of sonoelastography for the detection and staging of liver fibrosis